and mechanisms of action of mTOR inhibitors currently available for clinical use are described. Summary. mTOR is a target for anticancer agents due to its role in cancer development, progression ...
11h
Celcuity (CELC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oliver McCammon ...
Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...
In an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with ...
discloses that mammalian target of rapamycin (mTOR) kinase inhibition may be a useful targeted therapy for tuberous sclerosis ...
4d
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will attend the 2024 Child Neurology Society (CNS) ...
Thus far, inhibition of the mTOR pathway has focused on the use of rapamycin, along with three rapamycin analogues: temsirolimus, everolimus, and deforolimus. These agents have been studied as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback